



HAL
open science

Protein Quality Control Pathways at the Crossroad of Synucleinopathies

Eduardo P. de Mattos, Anne Wentink, Carmen Nussbaum-Krammer, Christian Hansen, Steven Bergink, Ronald Melki, Harm H. Kampinga

► **To cite this version:**

Eduardo P. de Mattos, Anne Wentink, Carmen Nussbaum-Krammer, Christian Hansen, Steven Bergink, et al.. Protein Quality Control Pathways at the Crossroad of Synucleinopathies. *Journal of Parkinson's disease*, In press, 14 pp. 10.3233/JPD-191790 . cea-02458907

HAL Id: cea-02458907

<https://cea.hal.science/cea-02458907v1>

Submitted on 29 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Review

Protein Quality Control Pathways at the Crossroad of Synucleinopathies

Eduardo P. De Mattos^a, Anne Wentink^b, Carmen Nussbaum-Krammer^b, Christian Hansen^c,
Steven Bergink^a, Ronald Melki^d and Harm H. Kampinga^{a,*}

^a*Department of Biomedical Sciences of Cells & Systems, University Medical Center Groningen, University of Groningen, Groningen, Netherlands*

^b*Center for Molecular Biology of Heidelberg University (ZMBH), and German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance, Heidelberg, Germany*

^c*Molecular Neurobiology, Department of Experimental Medical Science, Lund, Sweden*

^d*Institute Francois Jacob (MIRCE), CEA and Laboratory of Neurodegenerative Diseases, CNRS, Fontenay-Aux-Roses Cedex, France*

Accepted 2 January 2020

Abstract. The pathophysiology of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and many others converge at alpha-synuclein (α -Syn) aggregation. Although it is still not entirely clear what precise biophysical processes act as triggers, cumulative evidence points towards a crucial role for protein quality control (PQC) systems in modulating α -Syn aggregation and toxicity. These encompass distinct cellular strategies that tightly balance protein production, stability, and degradation, ultimately regulating α -Syn levels. Here, we review the main aspects of α -Syn biology, focusing on the cellular PQC components that are at the heart of recognizing and disposing toxic, aggregate-prone α -Syn assemblies: molecular chaperones and the ubiquitin-proteasome system and autophagy-lysosome pathway, respectively. A deeper understanding of these basic protein homeostasis mechanisms might contribute to the development of new therapeutic strategies envisioning the prevention and/or enhanced degradation of α -Syn aggregates.

Keywords: Alpha-synuclein, synucleinopathies, protein homeostasis, protein aggregation, molecular chaperones, ubiquitin-proteasome system, autophagy

INTRODUCTION

Alpha-synuclein (α -Syn) was first identified in human brain extracts more than 25 years ago [1, 2], and since then many physiological roles have been ascribed to this small protein. Although α -Syn has no defined tridimensional structure in aqueous solution [3] and is soluble under most physiological conditions [4], it can adopt beta-strand rich conformations

favoring the formation of amyloid fibrils in several neurodegenerative diseases, collectively known as synucleinopathies [5–7]. For instance, α -Syn aggregates are found in distinctive neuronal structures known as Lewy bodies (LBs) and Lewy neurites (LNs) in idiopathic and familial forms of Parkinson's disease (PD) and dementia with Lewy bodies [8], and in glial cytoplasmic inclusions in multiple system atrophy [9–12]. However, instead of being able to adopt only one type of structure, recent studies revealed that aggregated α -Syn possess distinct conformations (polymorphs) with unique cytotoxicity profiles [13–17]. This suggests that different synu-

*Correspondence to: Harm H. Kampinga, Ant. Deusinglaan 1, Building 3215, 5th Floor, FB30, 9713 AV Groningen, Netherlands. Tel.: +31 50 3616143; Fax: +31 50 3616111; E-mail: h.h.kampinga@umcg.nl

cleinopathies arise from distinct α -Syn polymorphs, as indeed proposed by experiments in animal models [18, 19].

Although the initial events leading to α -Syn aggregation and toxicity *in vivo* are still poorly understood, several lines of evidence suggest that cellular protein quality control (PQC) pathways play a central role in these processes. Among these are the molecular chaperones and the two main protein degradation pathways, namely the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) [20]. Here, we review basic molecular and cellular principles of α -Syn aggregation and their connection with PQC components, with a special emphasis on the suppression of α -Syn aggregation and/or toxicity by molecular chaperones.

ALPHA-SYNUCLEIN STRUCTURE AND FUNCTION

The N-terminal domain of α -Syn contains several motifs with amphipathic properties allowing for interactions with membranes (binding to lipid vesicles) and that can serve in protein-protein interactions [21] (Fig. 1). The central portion (residues 61 to 95) contains the non-amyloid-beta component of Alzheimer's disease amyloid (NAC) motif [1], which is both sufficient and required for amyloid formation [6, 22–24]. The C-terminal region has an important role in shielding the NAC motif from aggregation [6, 24]. Deletion of only the last 10 amino acids is already sufficient to accelerate α -Syn aggregation *in vitro*, and this effect is stronger upon larger C-terminal truncations up to amino acids 102–120 [24–26]. α -Syn is subject to several post-translational modifications (PTMs), including N-terminal acetylation, ubiquitylation, SUMOylation, nitration, and phosphorylation [27–32], with diverse consequences for its function and propensity to aggregate (detailed below). Several roles

have been ascribed to α -Syn, including facilitating the assembly of N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-complexes at presynaptic neuron terminals that mediate release of neurotransmitters [33, 34], and induction of membrane curvatures [35], among many others [36].

SNCA MUTATIONS REVEAL UNIQUE FEATURES OF α -SYN TOXICITY AND AGGREGATION

Two types of mutations in the *SNCA* gene have been linked to autosomal dominant forms of PD, highlighting distinct mechanisms by which α -Syn aggregation can be triggered: (i) increased gene dosage and (ii) point mutations enhancing α -Syn aggregation propensity. The latter, including A30P [37], E46K [38], H50Q [39, 40], G51D [41], and A53T [42], A53V [43], and A53E [44] (see Fig. 1), have been discovered by genetic screens in families with hereditary PD and directly influence α -Syn aggregation to different extents and via discrete pathways [45]. Mutants such as α -Syn^{A53T} largely enhance α -Syn aggregation into fibrils [45, 46], most likely by changing the conformational landscape that α -Syn populates towards aggregation-prone conformers, without disrupting vesicular interactions [21]. In contrast, the A30P mutation does not markedly modulate α -Syn aggregation compared to overexpression of α -Syn^{WT} in cellular models [46–48]. Instead, it abolishes α -Syn interaction with lipid vesicles both *in vitro* [21, 49] and *in vivo* [50], which may lead to a buildup of cytosolic α -Syn levels, and eventually contributes to α -Syn aggregation. This implies that α -Syn aggregation is also extremely dependent on its concentration and can even be triggered by the wild type protein [50, 51]. In fact, familial PD cases caused by duplications or triplications of the *SNCA* locus have been identified [52–56],




Fig. 1. Domain structure of the human alpha-synuclein (α -Syn) protein. α -Syn comprises three basic domains: an N-terminal amphipathic region, a central non- β -amyloid component (NAC) domain, and a C-terminal acidic domain. Seven membrane-interacting amino acid motifs are also present in the first half of the protein. The region preceding the NAC domain concentrates all pathogenic α -Syn mutations identified so far. Numbers on the upper part of the structure refer to amino acid positions.

with increased gene dosage correlating with earlier age at onset of disease [57].

MODELLING α -SYN AGGREGATION: SEEDED VERSUS NON-SEEDED CONDITIONS

As for any aggregation-prone protein, α -Syn molecules adopt conformations that allow the establishment of non-native interactions between molecules and their coalescence into thermodynamically unstable assemblies [58]. It is upon conformational transition to more regular and complementary interfaces [59] that stable seeds are generated, capable of acting as conformational template of the amyloid state [58]. In contrast, the highly stable preformed α -Syn aggregates commonly used in studies grow by incorporation of α -Syn molecules to their ends, as the binding of additional molecules to fibrillar ends generates an incorporation site for another molecule [58]. The spontaneous aggregation of α -Syn into amyloid fibrils thus is a multi-step process during which various intermediates are generated that provide copious opportunities for PQC interference.

The exogenous provision of preformed fibrils (seeded aggregation) bypasses the initial requirement for seed formation and allows the rapid incorporation of α -Syn monomers to their ends [58], presenting a more limited number of conformational states at which PQC components can interfere. The molecular mechanisms of chaperone modulation of α -Syn aggregation in spontaneous *versus* seeded aggregation are thus likely to differ significantly. Indeed, some chaperones interfere with unseeded aggregation (e.g., DNAJB6 [60]), whilst others selectively act on the elongation of preformed seeds (e.g., HSPB5 [61]).

The distinction between unseeded and seeded α -Syn aggregation is thus extremely important to our understanding of the α -Syn aggregation process and PQC effects thereon. Cellular studies aimed at investigating PQC components in α -Syn aggregation are most often unable to clearly determine whether unseeded, seeded or both processes are targeted and to what extent.

Non-seeded α -Syn aggregation

It has been surprisingly difficult to consistently model spontaneous, non-seeded α -Syn aggregation in cellular and organismal models. In fact, recent nuclear magnetic resonance data showed that α -Syn

at physiological concentrations remains largely in a monomeric, highly dynamic state in cells [4]. Since the crowded cellular environment is expected to facilitate α -Syn aggregation, these data strongly suggest the existence of agents (such as molecular chaperones and protein degradation machineries) that efficiently counteract α -Syn aggregation under normal circumstances.

To date, most studies investigating *de novo*, non-seeded, α -Syn aggregation have relied on overexpression of either wild-type (WT) or mutant variants of α -Syn. In one of the earliest models, α -Syn inclusion formation was detected in human neuroglioma H4 cells and mouse primary cortical neurons only upon overexpression of α -Syn constructs (α -Syn^{WT}, α -Syn^{A30P}, or α -Syn^{A53T}) harboring distinct C-terminal tags of variable sizes, which affected proteasomal clearance [47]. Since untagged α -Syn variants remained soluble, the tag potentiated aggregation probably through the exposure of the NAC region. Others have employed the co-expression of α -Syn with distinct aggregation-prone proteins that co-localize with α -Syn in LBs to trigger inclusion formation, such as synphilin-1 [45, 62–65] and tubulin polymerization-promoting protein (TPPP/p25 α) [66], but it is not entirely clear whether these are indeed active drivers of α -Syn aggregation. Some studies have also used bimolecular fluorescence complementation assays to assess *de novo* α -Syn aggregation [45, 67, 68]. In these cases, fluorescence is reconstituted and detected upon co-expression of two α -Syn constructs fused to either the N- or C-terminus halves of a fluorescent protein (for example, the split Venus-system). However, it is still neither clear whether such assemblies are of fibrillar nature, as the interaction of little as two α -Syn molecules is already sufficient to reconstitute fluorescence, nor to what extent the reconstitution of the functional fluorescent protein drives assembly. Nevertheless, some degree of α -Syn fibrillation was detected upon overexpression of distinct split Venus- α -Syn in flies [68]. In any case, true detergent-insoluble α -Syn aggregates are either usually not observed in unseeded α -Syn models, or they comprise only a small fraction of the total α -Syn pool, highlighting the urgent need for better models to document α -Syn aggregation.

Seeded α -Syn aggregation

Seeded aggregation experiments have been instrumental in uncovering many of the basic principles

of α -Syn pathology (see for instance [26, 69–71]). Indeed, most of the α -Syn literature relies on experiments in which an exogenous source of α -Syn amyloid fibrils is administered to cells or animals in order to trigger aggregation of the endogenous α -Syn (i.e., the α -Syn pool generated by cells *de novo*, even if it consists of an artificial transgene). In these cases, exogenous α -Syn fibrils come from either *in vitro* reactions using recombinant α -Syn [69] or from fibrils isolated from animal models or human post-mortem tissue [19, 26, 72]. As stated above, structural differences of α -Syn fibrils may lead to different synucleinopathies [15, 73]. However, it should be noted that there is currently no evidence demonstrating that human pathology starts upon exposure to exogenous α -Syn seeds [36], suggesting that factors such as cellular stress may trigger the formation of the first α -Syn seeds.

α -SYN AGGREGATION AND TOXICITY IN THE CONTEXT OF PQC SYSTEMS

Molecular chaperones

Suppression of α -Syn aggregation by Hsp70 machines

Molecular chaperones are at the heart of several PQC pathways and have been extensively implicated as protective agents against protein aggregation and neurodegeneration [74]. Here, we will primarily focus on the action of Hsp70 machines on α -Syn aggregation and toxicity. The human genome encodes for multiple Hsp70 isoforms and these Hsp70s act with the help of many co-factors a system that we refer to as the Hsp70 machines.

Purified Hsp70s (e.g., HSPA1A or HSPA8) alone can almost completely block α -Syn fibrillation at substoichiometric ratios, generating small aggregates composed of both proteins [25, 75–77]. Interestingly, addition of recombinant Hsp70-interacting protein (Hip) to reactions containing Hsp70 and monomeric α -Syn completely blocked Hsp70 co-aggregation and led to sustained inhibition of α -Syn aggregation in an ATP-dependent manner [78], highlighting the importance of additional co-factors for maximal suppression of α -Syn aggregation by Hsp70 machines (see below). Purified Hsp70s (HSPA1A or HSPA8) have been shown to bind a range of α -Syn assemblies, including monomers [77], pre-fibrillar [76, 78], and fibrillar species [75, 79, 80]. α -Syn amino acid stretches that are bound by Hsp70s span residues 10–45 and 97–102 [77].

Besides the suppression of α -Syn nucleation, Hsp70s also bind to α -Syn seeds [75] and prevent fibril elongation [79, 80]. These latter findings are consistent with a holdase function of Hsp70s against α -Syn fibril elongation, possibly shielding fibrillar ends from further incorporation of α -Syn molecules [79, 80].

In cells, co-expression of Hsp70 decreased the amount of high molecular weight α -Syn species [64, 65], probably by stabilization of α -Syn in assembly-incompetent states [81]. This could account for decreased cytotoxicity of α -Syn upon overexpression of Hsp70 [65, 82]. Indeed, Hsp70 overexpression in primary neurons markedly decreased the size, but not the amount, of secreted α -Syn species [82]. Since Hsp70 was also detected in the culture medium, it was proposed to bind monomeric or low molecular weight pre-fibrillar α -Syn assemblies and prevent further aggregation into mature fibrils [82].

At the organismal level, mice overexpressing both α -Syn and the rat HspA1 showed a 2-fold reduction in 1% Triton-X100-insoluble α -Syn-containing aggregates, compared to animals expressing α -Syn only [65]. In the fruit fly *Drosophila melanogaster*, selective expression of α -Syn^{WT}, α -Syn^{A30P}, or α -Syn^{A53T} in dopaminergic neurons for 20 days led to a 50% cell loss, but this could be fully rescued by targeted co-expression of the human Hsp70 isoform HSPA1L [83]. Interestingly, despite its cytoprotective effects, HSPA1L did not inhibit α -Syn inclusion formation, but rather co-localized with α -Syn in LB-like structures, suggesting that Hsp70 binding reduced toxic interactions of α -Syn with other biomolecules. Such phenomenon is conserved from flies to humans, with evidence for the accumulation of not only Hsp70, but also its cochaperones Hsp40/DNAJs and Hsp110/NEFs, into LBs and LNs from patients with PD, dementia with Lewy bodies, and other synucleinopathies [63, 83]. Indeed, the titration of Hsp70s out of solution by misfolded α -Syn has been hypothesized to contribute to disease onset due to lowering of the functional pool of Hsp70 available for protein quality control pathways [78, 84].

In vitro, the suppression of α -Syn aggregation by either Hsp70 (HSPA1A) or Hsc70 (HSPA8) does not require ATP/ADP cycling [25, 75, 78, 80], nor cochaperones, such as DNAJB1 [78]. In fact, DNAJB1, which stimulates Hsp70 cycling, even counteracts such sequestering activity [76]. However, these factors are essential for the proper function of Hsp70 in quality control pathways *in vivo* [85]. Indeed, overexpression of other members from the family of

Hsp70 co-chaperones also successfully prevents α -Syn aggregation and/or toxicity in cell and mouse models of PD. Of special relevance in this context is the large family of Hsp40/DNAJ proteins, which are regarded as the main determinants of specificity of Hsp70 machines, since different DNAJs bind to distinct client proteins and deliver those to Hsp70 [85, 86]. Thus, DNAJs could be exploited to maximize the activity of Hsp70 machines towards specific substrates. For example, besides inhibiting α -Syn aggregation *in vitro* [76], DNAJB1 almost completely abolished α -Syn inclusion formation in cells overexpressing α -Syn [63]. This has also been shown for DNAJB6 and its close homologue DNAJB8 [51], both of which also strongly suppress the aggregation of other amyloidogenic polypeptides, including expanded polyglutamine-containing proteins [60, 87] and the amyloid-beta protein [88]. Interestingly, α -Syn aggregation was not suppressed by a DNAJB6 mutant that does not interact with Hsp70 [51], strengthening the notion that cooperation between distinct components of Hsp70 machines is essential for optimal function. Despite these examples, little is still known on the contribution of different DNAJs and/or NEFs to the Hsp70-dependent suppression of α -Syn aggregation *in vivo*. Similar to recently developed *in vitro* screens for inhibiting tau aggregation [89], or enhancing α -Syn disaggregation (see below) [90], further comparative studies using distinct compositions of Hsp70 machines are urgently required to better understand and manipulate Hsp70 machines in synucleinopathies.

Disaggregation of α -Syn fibrils by Hsp70 machines

The diversity and complexity of Hsp70 machines is also highlighted by studies investigating the potential of these systems to disaggregate pre-existing α -Syn amyloids. For instance, although Hsp70 alone does not modify or disaggregate mature α -Syn fibrils at relevant time-scales *in vitro* [75, 91], a specific Hsp70/HSPA-Hsp40/DNAJ-Hsp110/NEF combination showed powerful, ATP-dependent disaggregase activity against α -Syn amyloids [90]. Indeed, optimal fragmentation and depolymerization of α -Syn fibrils was detected upon combining Hsc70/HSPA8 with Hdj1/DNAJB1 and the NEF Apg2/HSPA4, but not upon addition of other Hsp70 machine members, such as Hsp70/HSPA1A, DNAJA1, DNAJA2, or BAG1. Moreover, a precise stoichiometry between these components was crucial for productive disaggregation [90, 91], further illustrating the tight balance

between specificity and levels of chaperones/co-chaperones for the activity of Hsp70 machines. It is still not known whether Hsp70-mediated disaggregation of α -Syn also occurs *in vivo*, but it is tempting to speculate that the breakup of fibrils into smaller, more soluble assemblies facilitates their processing by downstream PQC components, as discussed below. However, it is equally possible that disaggregation could be detrimental and facilitate α -Syn seed propagation. Further studies are necessary to clarify these issues.

Clearance of α -Syn assemblies via protein degradation machineries

The two major cellular protein degradation machineries comprise the UPS and ALP, with the latter encompassing both autophagosome-dependent and independent pathways [92]. There is an intricate and tightly regulated crosstalk between proteasomal and lysosomal pathways engaged in the processing of α -Syn, as several studies reported preferential degradation of α -Syn via the UPS or ALP [31, 93–98]. Moreover, α -Syn (WT or distinct mutants) overexpression can impair the activity of both the UPS [99, 100] and distinct components of the ALP [66, 101–104], which would act in a progressive pathogenic feedback loop to accelerate aggregation and toxicity. Whether UPS or ALP lead to the degradation of α -Syn assemblies is still actively debated. Recent findings suggest, however, that the UPS has a more prominent role in degrading smaller α -Syn assemblies at least when protein quality systems are highly active, as is generally the case in young, healthy organisms [99]. Autophagic activity seems to be more required for larger α -Syn assemblies and upon increased α -Syn burden, due to either mutations that lead to α -Syn accumulation or decreased activity of other PQC components, as observed with aging [99]. α -Syn has also been shown to be recognized and degraded by other cellular (extracellular) proteases not directly linked to the UPS and ALP pathways [105, 106]. However, the extent to which such enzymes are required for proper α -Syn turnover and/or inhibition of propagation is still poorly understood.

PTMs also play a role in α -Syn processing and act as important sorting hubs to distinct protein degradation machineries. For instance, the covalent binding of ubiquitin to α -Syn, via either mono-(monoUb) or polyubiquitylation (polyUb) in distinct linkage types, has opposing consequences to the




Fig. 2. Targeting and processing of alpha-synuclein (α -Syn) by protein quality control (PQC) pathways. *Left*: in normal conditions, in which the cellular PQC capacity is in balance with the α -Syn burden, soluble as well as pre-fibrillar α -Syn assemblies (after disassembly) have been shown to be targeted to and degraded by several PQC components. The initial survey of α -Syn species might be performed by molecular chaperones (1), which can facilitate the sorting of α -Syn to distinct degradative routes, such as the ubiquitin-proteasome system (UPS; 2), a ubiquitin-independent proteasomal degradation pathway (3), chaperone-mediated autophagy (CMA; 4), macroautophagy (5), secretion via endosomes (6) [162], and proteolytic digestion by intracellular (7) or extracellular proteases. *Right*: in aged organisms or pathological conditions, the α -Syn burden surpasses the cellular PQC capacity, leading to α -Syn accumulation and subsequent aggregation. Fibrillar α -Syn assemblies can trap several biomolecules, including molecular chaperones (8), which contributes to chaperone depletion and decreases PQC capacity. Similarly, α -Syn aggregation has been linked to impairment of different steps of macroautophagy (9), CMA (10), and proteasomal degradation (11). In some experimental setups, increased α -Syn levels can also lead to increased autophagic flux and destruction of organelles, such as mitochondria (12). α -Syn species can also be secreted to the extracellular space and taken up by neighboring cells (13), where they seed the aggregation of soluble α -Syn species (14). α -Syn aggregation additionally impairs the intracellular trafficking of other proteins, such as the lysosomal enzyme glucocerebrosidase (GCCase; 15). Decreased lysosomal GCCase activity, due to either mislocalization of wildtype (wt) GCCase or mutant GCCase variants (16), leads to accumulation of GCCase substrates (such as glycosylceramide; 17), which might potentiate α -Syn aggregation. See main text for further mechanistic details and references. ER: endoplasmic reticulum; Hsc70: heat shock cognate 71 kDa protein; LAMP2a: lysosome-associated membrane protein 2 isoform a; poly-Ub: poly-ubiquitin.

421 fate of α -Syn. For instance, the co-chaperone CHIP
 422 (carboxyl terminus of Hsp70-interacting protein),
 423 a ubiquitous E3 Ub-ligase and crucial downstream
 424 effector of Hsp70 machineries [85], was shown to
 425 promote α -Syn degradation via both the UPS and
 426 ALP [107]. Also, while monoubiquitylation by the
 427 E3 ubiquitin-ligase SIAH targeted α -Syn to the UPS,
 428 removal of the ubiquitin moiety by the deubiquitylase
 429 USP9X favored α -Syn degradation via macroau-
 430 tophagy [108]. Yet another ubiquitin-ligase (Nedd4)
 431 facilitated the binding of K63-linked polyUb chains
 432 to α -Syn and promoted its lysosomal degradation
 433 via the ESCRT pathway [109]. Depending on its
 434 assembly state, other PTMs such as SUMOylation,
 435 phosphorylation, nitration, O-GlcNAcylation, oxida-
 436 tion, and dopamine-modification can also modulate

437 α -Syn processing via downstream degradation path-
 438 ways [30, 31, 110–114]. In this context, the main
 439 findings associated to the partition of α -Syn between
 440 the UPS and ALP are discussed below and illustrated
 441 in Fig. 2.

442 Ubiquitin-proteasome system

443 In mammalian cells, the central player of the UPS
 444 is the 26S proteasome, a large, ATP-dependent multi-
 445 protein complex devoted to the selective destruction
 446 of target proteins [115]. Evidence for the degrada-
 447 tion of α -Syn via proteasomes comes from both
 448 *in vitro* [116] and cellular studies [117–119], with
 449 not only monomeric, but maybe also pre-fibrillar α -
 450 Syn species (after dissociation) being targeted to this
 451 pathway [30, 100]. Several Ub-ligases interact with

452 α -Syn and catalyze the addition of either mono- or
453 polyUb chains with either cytoprotective or toxic con-
454 sequences depending on the specific experimental
455 setup, presumably due to differential impact on cellular
456 α -Syn half-life [109, 117, 120, 121]. Unmodified
457 α -Syn can also be degraded by proteasomes via an
458 Ub-independent pathway [118], particularly relevant
459 for phosphorylated α -Syn at serine 129 (α -Syn^{PS129})
460 [119]. A mutant mimicking α -Syn^{PS129} (α -Syn^{S129E})
461 was shown to be a poor autophagic substrate [111],
462 re-emphasizing the complementary importance of the
463 different degradation pathways. Several lines of evi-
464 dence also suggest that an increased α -Syn burden
465 inhibits proteasomal activity, which in turn might
466 lead to a further increase in α -Syn levels, thus estab-
467 lishing a pathogenic feedback loop favoring α -Syn
468 aggregation [100, 104, 122, 123].

469 *Autophagy-lysosome pathway*

470 The numerous reports on α -Syn degradation via
471 the ALP highlight the importance of lysosomal-
472 dependent regulation of α -Syn levels [124]. Not
473 surprisingly, a plethora of therapeutic strategies
474 targeting the ALP have been explored to tackle α -
475 Syn aggregation and toxicity (reviewed in [125]).
476 The ALP comprises catabolic processes that con-
477 verge at the lysosome, being usually divided
478 in three distinct types: macroautophagy, microau-
479 topophagy, and chaperone-mediated autophagy (CMA)
480 [126]. Macroautophagy relies on the engulfment
481 of substrates within autophagosomes, which are
482 double-layered membrane vesicles that sequester
483 intracellular components and target them to lyso-
484 somes for degradation [127]. Most long-lived
485 proteins, protein aggregates and even whole damaged
486 organelles are degraded via macroautophagy [92,
487 128]. The importance of macroautophagy for nor-
488 mal cellular function is exemplified by experiments
489 in which loss of macroautophagy in neurons led to
490 accumulation of ubiquitylated proteins and inclu-
491 sion bodies, and neurodegeneration [129]. Moreover,
492 mutations in different autophagy-related genes, such
493 as *ATG5*, lead to genetic diseases with neurologic
494 phenotypes in humans [130].

495 Data supporting a role for macroautophagy in
496 the degradation of monomeric and pre-fibrillar α -
497 Syn assemblies come mainly from studies detecting
498 α -Syn buildup upon exposure of cell lines over-
499 expressing either WT or mutant α -Syn variants
500 to the inhibitor of autophagosome formation 3-
501 methyladenine [93, 95, 97, 131]. *In vivo*, overexpres-
502 sion of beclin-1, which is involved in autophagosome

503 formation via the phosphatidylinositol 3-phosphate
504 kinase complex, rescued neurological deficits of α -
505 Syn transgenic mice [131]. Yet, beclin-1 is involved
506 in other endosomal pathways, not directly linked to
507 macroautophagy [132], which may contribute to the
508 reduction of α -Syn levels and improved performance
509 of animals overexpressing α -Syn [131]. Impairment
510 of lysosomes, toward which all ALP components
511 converge, with bafilomycin A1 also resulted in α -Syn
512 buildup, further supporting a role for the ALP in α -
513 Syn degradation [96, 125, 133, 134]. Nonetheless,
514 whether macroautophagy is capable of degrading
515 aggregated, insoluble α -Syn assemblies, such as
516 those present in LBs, is still debated. For instance, in
517 a cell model of endogenous α -Syn aggregation upon
518 exposure to exogenous α -Syn pre-formed fibrils, α -
519 Syn inclusion resisted lysosomal degradation [134].
520 In addition, increasing macroautophagy flux upon
521 α -Syn overexpression was also shown to have detri-
522 mental effects, ranging from increased degradation of
523 mitochondria (mitophagy) in both cellular [135], and
524 animal models of PD [136] to enhanced secretion of
525 α -Syn assemblies to the extracellular space [66], that
526 may contribute to the spreading of pathogenic α -Syn
527 aggregates. On the other hand, Gao and colleagues
528 (2019) have recently demonstrated enhanced degra-
529 dation of internalized exogenous α -Syn pre-formed
530 fibrils in neuronal cell lines upon treatment with dif-
531 ferent autophagy inducers, suggesting that lysosomes
532 might be capable of clearing seeded fibrillar α -Syn
533 [137].

534 Different from macroautophagy, CMA encom-
535 passes the selective targeting of substrates to lyso-
536 somes via Hsc70 (HSPA8) and its co-chaperones, to
537 specifically recognize cargo proteins with a KFERQ-
538 like pentapeptide motif, and lysosomal-associated
539 membrane protein 2a (LAMP2a)-mediated substrate
540 translocation across lysosomal membranes [138,
541 139]. Several lines of evidence support the involve-
542 ment of CMA in the processing of α -Syn [125].
543 In an *in vitro* lysosomal reconstitution assay, α -
544 Syn^{WT} was selectively targeted to lysosomes by
545 LAMP2a, and mutations within a KFERQ-like motif
546 in α -Syn C-terminus abolished this activity [94].
547 In cultured cells overexpressing α -Syn, macroau-
548 topophagy inhibition led to higher α -Syn clearance
549 via CMA [95, 140], while α -Syn protein levels
550 were increased upon specific knockdown of LAMP2a
551 [141], or HSPA8 [141, 142]. Compared to healthy
552 controls, lower LAMP2a protein levels were detected
553 in brains from early-stage PD patients, accompanied
554 by a buildup of α -Syn and other known CMA sub-

strates, such as myocyte-specific enhancer factor 2D (MEF2D) and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha ($\text{I}\kappa\text{B}\alpha$) [143]. The importance of CMA in processing α -Syn monomers and dimers, but not pre-fibrillar assemblies [111], is somewhat diminished by the finding that α -Syn steady-state levels were unchanged in *Lamp2* knockout mice [144]. This however may be due to developmental adaptations in other PQC components, such as the UPS, as outlined above, thus masking the influence of CMA. Indeed, *in vivo* down-regulation of *Lamp2a* in rats resulted in accumulation of ubiquitin-positive α -Syn inclusions in the *substantia nigra* followed by loss of dopaminergic neurons [145]. Additional evidence for CMA involvement in α -Syn degradation comes from observations that distinct PTMs, including oxidation, nitration, and modification by oxidized dopamine, impair α -Syn degradation via CMA, resulting in its buildup [111]. Importantly, similar to the rare α -Syn^{A30P} and α -Syn^{A53T} mutations [94], dopamine-modified α -Syn (present in sporadic PD cases) also interferes with the processing of other CMA substrates [111], further contributing to the imbalance of protein homeostasis.

Upon convergence of distinct ALP routes at lysosomes, soluble α -Syn assemblies can be degraded by acidic proteases, such as cathepsin D [146–148]. Another lysosomal enzyme that has attracted much attention in synucleinopathies is glucocerebrosidase (GCase). While homozygous mutations in the GCase-encoding gene *GBA1* cause Gaucher's disease [149], heterozygous mutations are a well-established risk factor for developing PD [150]. Indeed, α -Syn buildup is observed in several models of GCase deficiency. This occurs upon pharmacological inhibition of GCase activity in cultured cells [151, 152] and also in *GBA1* mutant backgrounds, both in mouse models overexpressing α -Syn [153–155] and in PD patient iPS-derived dopaminergic neurons [156, 157]. α -Syn buildup impairs GCase trafficking and targeting to lysosomes [158, 159]. Conversely, rescue of GCase activity in mice overexpressing α -Syn^{A53T} reduced α -Syn levels and toxicity [155], establishing a pathogenic feedback loop that promotes loss of GCase function, and α -Syn accumulation, aggregation and, potentially, cell-to-cell transmission of α -Syn seeds [160, 161]. Altogether, these results suggest that the upregulation of autophagy without a simultaneous improvement of lysosomal capacity might not be a true therapeutic strategy in synucleinopathies.

CONCLUDING REMARKS

The topics discussed here paint a complex picture of cellular strategies engaged in the tight regulation of α -Syn protein levels, which ultimately determine its aggregation propensity and associated toxicity. Even though there are still some fundamental gaps in our understanding of α -Syn biology, it has become increasingly clear that the activity of dedicated PQC components, such as molecular chaperones, the UPS, and ALP is a crucial line of defense against α -Syn-mediated pathology. Failure of these systems (e.g., due to cellular stress, genetic predisposition, or aging) will influence α -Syn levels and solubility, eventually leading to disease. However, it is tempting to envision that novel therapeutic strategies to prevent, slow down and/or halt progression of synucleinopathies will emerge based on our understanding of protein homeostasis in general and in particular in components that prevent initiation of α -Syn protein aggregation or help clearing them before they affect neuronal health and synaptic integrity.

ACKNOWLEDGMENTS

This is an EU Joint Program – Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND – www.jpnd.eu. France, National Research Agency (ANR); Germany, Federal Ministry of Education and Research (BMBF); Netherlands, Netherlands Organization for Scientific Research (ZonMw); Sweden, Swedish Research Council (VR). We would also like to acknowledge Prof. Bernd Bukau for his support and the Deutsche Forschungsgemeinschaft (SFB1036), AmPro program of the Helmholtz Society and the Landesstiftung Baden-Württemberg.

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

- [1] Uéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc Natl Acad Sci U S A* **90**, 11282–11286.
- [2] Jakes R, Spillantini MG, Goedert M (1994) Identification of two distinct synucleins from human brain. *FEBS Lett* **345**, 27–32.

- 652 [3] Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury
653 PT (1996) NACP, a protein implicated in Alzheimer's dis-
654 ease and learning, is natively unfolded. *Biochemistry* **35**,
655 13709-13715.
- 656 [4] Theillet F-X, Binolfi A, Bekei B, Martorana A, Rose HM,
657 Stuijver M, Verzini S, Lorenz D, van Rossum M, Goldfarb
658 D, Selenko P (2016) Structural disorder of monomeric α -
659 synuclein persists in mammalian cells. *Nature* **530**, 45-50.
- 660 [5] Vilar M, Chou H-T, Lühns T, Maji SK, Riek-Loher D,
661 Verel R, Manning G, Stahlberg H, Riek R (2008) The fold
662 of alpha-synuclein fibrils. *Proc Natl Acad Sci U S A* **105**,
663 8637-8642.
- 664 [6] Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes
665 FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang
666 M, Jiang L, Arbing MA, Nannenga BL, Hattne J, White-
667 legge J, Brewster AS, Messerschmidt M, Boutet S, Sauter
668 NK, Gonen T, Eisenberg DS (2015) Structure of the toxic
669 core of α -synuclein from invisible crystals. *Nature* **525**,
670 486-490.
- 671 [7] Goedert M, Jakes R, Spillantini MG (2017) The synucle-
672 inopathies: Twenty years on. *J Parkinsons Dis* **7**, S51-S69.
- 673 [8] Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ,
674 Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bod-
675 ies. *Nature* **388**, 839-840.
- 676 [9] Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H
677 (1998) α -Synuclein immunoreactivity in glial cytoplasmic
678 inclusions in multiple system atrophy. *Neurosci Lett*
679 **249**, 180-182.
- 680 [10] Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S,
681 Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VMY (1998)
682 Glial cytoplasmic inclusions in white matter oligodendro-
683 cytes of multiple system atrophy brains contain insoluble
684 α -synuclein. *Ann Neurol* **44**, 415-422.
- 685 [11] Arima K, Uáda K, Sunohara N, Arakawa K, Hirai S,
686 Nakamura M, Tonozuka-Uehara H, Kawai M (1998)
687 NACP/ α -synuclein immunoreactivity in fibrillary com-
688 ponents of neuronal and oligodendroglial cytoplasmic
689 inclusions in the pontine nuclei in multiple system atrophy.
690 *Acta Neuropathol* **96**, 439-444.
- 691 [12] Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos
692 PL, Goedert M (1998) Filamentous α -synuclein inclusions
693 link multiple system atrophy with Parkinson's disease and
694 dementia with Lewy bodies. *Neurosci Lett* **251**, 205-208.
- 695 [13] Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH,
696 Habenstein B, Madiona K, Olieric V, Böckmann A, Meier
697 BH, Melki R (2013) Structural and functional character-
698 ization of two alpha-synuclein strains. *Nat Commun* **4**,
699 2575.
- 700 [14] Li B, Ge P, Murray KA, Sheth P, Zhang M, Nair G, Sawaya
701 MR, Shin WS, Boyer DR, Ye S, Eisenberg DS, Zhou ZH,
702 Jiang L (2018) Cryo-EM of full-length α -synuclein reveals
703 fibril polymorphs with a common structural kernel. *Nat*
704 *Commun* **9**, 3609.
- 705 [15] Peelaerts W, Bousset L, Van der Perren A, Moskalyuk
706 A, Pulizzi R, Giugliano M, Van den Haute C, Melki R,
707 Baekelandt V (2015) α -Synuclein strains cause distinct
708 synucleinopathies after local and systemic administration.
709 *Nature* **522**, 340-344.
- 710 [16] Guerrero-Ferreira R, Taylor NM, Mona D, Ringler P,
711 Lauer ME, Riek R, Britschgi M, Stahlberg H (2018) Cryo-
712 EM structure of alpha-synuclein fibrils. *Elife* **7**, e36402.
- 713 [17] Guerrero-Ferreira R, Taylor NMI, Arteni A-A, Kumari P,
714 Mona D, Ringler P, Britschgi M, Lauer ME, Verasdock
715 J, Riek R, Melki R, Meier BH, Böckmann A, Bousset
716 L, Stahlberg H (2019) Two new polymorphic structures
of alpha-synuclein solved by cryo-electron microscopy. *717*
bioRxiv, <https://doi.org/10.1101/654582> *718*
- [18] Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero *719*
S, Pérez-Villalba A, Fernandez PO, Blesa J, Parent A, Perier *720*
C, Farías JA, Obeso JA, Bezard E, Vila M (2014) Lewy *721*
body extracts from Parkinson disease brains trigger α - *722*
synuclein pathology and neurodegeneration in mice and *723*
monkeys. *Ann Neurol* **75**, 351-362. *724*
- [19] Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, *725*
Gentleman SM, DeArmond SJ, Prusiner SB (2013) Trans- *726*
mission of multiple system atrophy prions to transgenic *727*
mice. *Proc Natl Acad Sci U S A* **110**, 19555-19560. *728*
- [20] Balchin D, Hayer-Hartl M, Hartl FU (2016) In vivo *729*
aspects of protein folding and quality control. *Science* **353**, *730*
aac4354. *731*
- [21] Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M *732*
(1998) Binding of α -synuclein to brain vesicles is abol- *733*
ished by familial Parkinson's disease mutation. *J Biol* *734*
Chem **273**, 26292-26294. *735*
- [22] Iwai A, Yoshimoto M, Masliah E, Saitoh T (1995) Non- *736*
a β component of Alzheimer's disease amyloid (NAC) is *737*
amyloidogenic. *Biochemistry* **34**, 10139-10145. *738*
- [23] Giasson BI, Murray IVJ, Trojanowski JQ, Lee VMY *739*
(2001) A hydrophobic stretch of 12 amino acid residues in *740*
the middle of α -synuclein is essential for filament assem- *741*
bly. *J Biol Chem* **276**, 2380-2386. *742*
- [24] Murray IVJ, Giasson BI, Quinn SM, Koppaka V, Axelsen *743*
PH, Ischiropoulos H, Trojanowski JQ, Lee VM-Y (2003) *744*
Role of alpha-synuclein carboxy-terminus on fibril forma- *745*
tion in vitro. *Biochemistry* **42**, 8530-8540. *746*
- [25] Luk KC, Mills IP, Trojanowski JQ, Lee VM-Y (2008) *747*
Interactions between Hsp70 and the hydrophobic core of *748*
alpha-synuclein inhibit fibril assembly. *Biochemistry* **47**, *749*
12614-12625. *750*
- [26] Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, *751*
Lee VMY (2012) Intracerebral inoculation of pathological *752*
 α -synuclein initiates a rapidly progressive neurodegenera- *753*
tive α -synucleinopathy in mice. *J Exp Med* **209**, 975-986. *754*
- [27] Bhattacharjee P, Öhrfelt A, Lashley T, Blennow K, *755*
Brinkmalm A, Zetterberg H (2019) Mass spectrometric *756*
analysis of Lewy body-enriched α -synuclein in Parkin- *757*
son's disease. *J Proteome Res* **18**, 2109-2120. *758*
- [28] Kellie JF, Higgs RE, Ryder JW, Major A, Beach TG, *759*
Adler CH, Merchant K, Knierman MD (2014) Quanti- *760*
tative measurement of intact alpha-synuclein proteoforms *761*
from post-mortem control and Parkinson's disease brain *762*
tissue by intact protein mass spectrometry. *Sci Rep* **4**, 5797. *763*
- [29] Rott R, Szargel R, Shani V, Hamza H, Savyon M, *764*
Abd Elghani F, Bandopadhyay R, Engelender S (2017) *765*
SUMOylation and ubiquitination reciprocally regulate α - *766*
synuclein degradation and pathological aggregation. *Proc* *767*
Natl Acad Sci U S A **114**, 13176-13181. *768*
- [30] Shahpasandzadeh H, Popova B, Kleinknecht A, Fraser *769*
PE, Outeiro TF, Braus GH (2014) Interplay between *770*
sumoylation and phosphorylation for protection against *771*
 α -synuclein inclusions. *J Biol Chem* **289**, 31224-31240. *772*
- [31] Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, *773*
Rueter SM, Trojanowski JQ, Lee VM-Y, Ischiropoulos H *774*
(2001) Induction of alpha-synuclein aggregation by intra- *775*
cellular nitrate insult. *J Neurosci* **21**, 8053-8061. *776*
- [32] Anderson JP, Walker DE, Goldstein JM, De Laat R, Ban- *777*
ducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee *778*
M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher *779*
MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote *780*
TJ (2006) Phosphorylation of Ser-129 is the dominant *781*

- pathological modification of α -synuclein in familial and sporadic lewy body disease. *J Biol Chem* **281**, 29739-29752.
- [33] Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. *Science* **329**, 1663-1667.
- [34] Burré J, Sharma M, Südhof TC (2014) α -Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. *Proc Natl Acad Sci U S A* **111**, E4274-4283.
- [35] Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, Petrlova J, Voss JC, Stamou DG, Steven AC, Langen R (2010) Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. *J Biol Chem* **285**, 32486-32493.
- [36] Peelaerts W, Bousset L, Baekelandt V, Melki R (2018) α -Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: Similarities and differences. *Cell Tissue Res* **373**, 195-212.
- [37] Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Eppelen JT, Schöls L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat Genet* **18**, 106-108.
- [38] Lezcano E, Vidal L, Ser T del, Tortosa EG, Llorens V, Atarés B, Hoenicka J, Ampuero I, Rodríguez O, Muñoz DG, Zarranz JJ, Gómez-Esteban JC, Yébenes de JG, Alegre J, Ros R (2004) The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. *Ann Neurol* **55**, 164-173.
- [39] Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH (2013) A novel α -synuclein missense mutation in Parkinson disease. *Neurology* **80**, 1062-1064.
- [40] Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A, Farrer MJ (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. *Mov Disord* **28**, 811-813.
- [41] Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N, Pieri L, Madiona K, Dürr A, Melki R, Vermy C, Brice A, French Parkinson's Disease Genetics Study Group (2013) G51D α -synuclein mutation causes a novel parkinsonian-pyramidal syndrome. *Ann Neurol* **73**, 459-471.
- [42] Polymeropoulos MH, Lavedan C, Hollmann M, Glutamate I, Silva AJ, Stevens CF, Toneygawa S, Wang Y, Mayford M, Kandel ER, Dell TJO, Patton BL, Malloy SS, Kennedy MB, Biol M, Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Iorio G Di, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* **276**, 2045-2048.
- [43] Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, Farrer MJ, Nishioka K, Hattori N (2017) Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. *Neurobiol Aging* **57**, 248.e7-248.e12.
- [44] Picillo M, Lizarraga KJ, Friesen EL, Chau H, Zhang M, Sato C, Rooke G, Munhoz RP, Rogaeva E, Fraser PE, Kalia SK, Kalia LV (2018) Parkinsonism due to A53E α -synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. *Mov Disord* **33**, 1950-1955.
- [45] Lázaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, Gerhardt E, Kröhnert K, Klucken J, Pereira MD, Popova B, Kruse N, Mollenhauer B, Rizzoli SO, Braus GH, Danzer KM, Outeiro TF (2014) Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. *PLoS Genet* **10**, e1004741.
- [46] Conway KA, Harper JD, Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant α -synuclein linked to early-onset Parkinson disease. *Nat Med* **4**, 1318-1320.
- [47] McLean PJ, Kawamata H, Hyman BT (2001) Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. *Neuroscience* **104**, 901-912.
- [48] Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. *Proc Natl Acad Sci U S A* **97**, 571-576.
- [49] Samuel F, Flavin WP, Iqbal S, Pacelli C, Renganathan SDS, Trudeau LE, Campbell EM, Fraser PE, Tandon A (2016) Effects of serine 129 phosphorylation on α -synuclein aggregation, membrane association, and internalization. *J Biol Chem* **291**, 4374-4385.
- [50] Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science* **302**, 1772-1775.
- [51] Aprile FA, Källstig E, Limorenko G, Vendruscolo M, Ron D, Hansen C (2017) The molecular chaperones DNAJB6 and Hsp70 cooperate to suppress α -synuclein aggregation. *Sci Rep* **7**, 1-11.
- [52] Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muentner M, Baptista M, Miller D, Blacato J, Hardy J, Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. *Science* **302**, 841.
- [53] Nishioka K, Ross OA, Ishii K, Kachergus JM, Ishiwata K, Kitagawa M, Kono S, Obi T, Mizoguchi K, Inoue Y, Imai H, Takanashi M, Mizuno Y, Farrer MJ, Hattori N (2009) Expanding the clinical phenotype of SNCA duplication carriers. *Mov Disord* **24**, 1811-1819.
- [54] Ibáñez P, Bonnet A-M, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. *Lancet* **364**, 1169-1171.
- [55] Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK (2016) Autosomal dominant Parkinson's disease caused by SNCA duplications. *Parkinsonism Relat Disord* **22** Suppl 1, S1-S6.
- [56] Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson E-M, Schüle B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. *Neurology* **68**, 916-922.
- [57] Book A, Guella I, Candido T, Brice A, Hattori N, Jeon B, Farrer MJ, SNCA Multiplication Investigators of the GEOPD Consortium (2018) A meta-analysis of α -synuclein multiplication in familial parkinsonism. *Front Neurol* **9**, 1021.

- 912 [58] Oosawa F, Asakura S (1975) *Thermodynamics of the Poly-*
913 *merization of Protein*, Academic Press, London.
- 914 [59] Cremades N, Cohen SIA, Deas E, Abramov AY, Chen
915 AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA,
916 Bertocini CW, Wood NW, Knowles TPJ, Dobson CM,
917 Klenerman D (2012) Direct observation of the intercon-
918 version of normal and toxic forms of α -synuclein. *Cell*
919 **149**, 1048-1059.
- 920 [60] Kakkar V, Månsson C, de Mattos EP, Bergink S, van der
921 Zwaag M, van Waarde MAWH, Kloosterhuis NJ, Melki R,
922 van Cruchten RTP, Al-Karadaghi S, Arosio P, Dobson CM,
923 Knowles TPJ, Bates GP, van Deursen JM, Linse S, van de
924 Sluis B, Emanuelsson C, Kampinga HH (2016) The S/T-
925 rich motif in the DNAJB6 chaperone delays polyglutamine
926 aggregation and the onset of disease in a mouse model. *Mol*
927 *Cell* **62**, 272-283.
- 928 [61] Waudby CA, Knowles TPJ, Devlin GL, Skepper JN,
929 Ecroyd H, Carver JA, Welland ME, Christodoulou J,
930 Dobson CM, Meehan S (2010) The interaction of alphaB-
931 crystallin with mature alpha-synuclein amyloid fibrils
932 inhibits their elongation. *Biophys J* **98**, 843-851.
- 933 [62] Shin Y, Klucken J, Patterson C, Hyman BT, McLean
934 PJ (2005) The Co-chaperone carboxyl terminus of
935 Hsp70-interacting protein (CHIP) mediates α -synuclein
936 degradation decisions between proteasomal and lysosomal
937 pathways. *J Biol Chem* **280**, 23727-23734.
- 938 [63] McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma
939 N, Ueda K, Breakefield XO, Hyman BT (2002) TorsinA
940 and heat shock proteins act as molecular chaperones: Sup-
941 pression of alpha-synuclein aggregation. *J Neurochem* **83**,
942 846-854.
- 943 [64] Klucken J, Shin Y, Hyman BT, McLean PJ (2004) A single
944 amino acid substitution differentiates Hsp70-dependent
945 effects on α -synuclein degradation and toxicity. *Biochem*
946 *Biophys Res Commun* **325**, 367-373.
- 947 [65] Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ
948 (2004) Hsp70 reduces alpha-synuclein aggregation and
949 toxicity. *J Biol Chem* **279**, 25497-25502.
- 950 [66] Ejlerskov P, Rasmussen I, Nielsen TT, Bergström AL,
951 Tohyama Y, Jensen PH, Vilhardt F (2013) Tubulin
952 polymerization-promoting protein (TPPP/p25 α) pro-
953 motes unconventional secretion of α -synuclein through
954 exophagy by impairing autophagosome-lysosome fusion.
955 *J Biol Chem* **288**, 17313-17335.
- 956 [67] Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M,
957 Carvalho F, Hyman BT, McLean PJ (2008) Formation of
958 toxic oligomeric α -synuclein species in living cells. *PLoS*
959 *One* **3**, e1867.
- 960 [68] Prasad V, Wasser Y, Hans F, Goswami A, Katona I, Out-
961 eiro TF, Kahle PJ, Schulz JB, Voigt A (2018) Monitoring
962 α -synuclein multimerization in vivo. *FASEB J* **33**, 2116-
963 2131.
- 964 [69] Luk KC, Kehm V, Carroll J, Zhang B, Brien PO, Tro-
965 janowski JQ, Lee VM (2012) Pathological α -synuclein
966 transmission in nontransgenic mice. *Science* **949**, 949-953.
- 967 [70] Hansen C, Angot E, Bergström A, Steiner JA, Pieri L,
968 Paul G, Outeiro TF, Melki R, Kallunki P, Fog K (2011)
969 a-synuclein propagates from mouse brain to grafted dop-
970 mainergic neurons and seeds aggregation in cultured
971 human cells. *J Clin Invest* **121**, 715-725.
- 972 [71] Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Rid-
973 dle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee
974 VM-Y (2011) Exogenous α -synuclein fibrils induce Lewy
975 body pathology leading to synaptic dysfunction and neu-
976 ron death. *Neuron* **72**, 57-71.
- [72] Bernis ME, Babila JT, Breid S, Wüsten KA, Wüllner
977 U, Tamgüney G (2015) Prion-like propagation of human
978 brain-derived alpha-synuclein in transgenic mice express-
979 ing human wild-type alpha-synuclein. *Acta Neuropathol*
980 *Commun* **3**, 75.
- [73] Prusiner SB, Woerman AL, Mordes DA, Watts JC, Ram-
981 persaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz
982 SN, Geschwind DH, Glidden DV, Halliday GM, Mid-
983 dleton LT, Gentleman SM, Grinberg LT, Giles K (2015)
984 Evidence for α -synuclein prions causing multiple system
985 atrophy in humans with parkinsonism. *Proc Nat. Acad Sci*
986 *U S A* **112**, E5308-E5317.
- [74] Kampinga HH, Bergink S (2016) Heat shock proteins as
987 potential targets for protective strategies in neurodegener-
988 ation. *Lancet Neurol* **15**, 748-759.
- [75] Huang C, Cheng H, Hao S, Zhou H, Zhang X, Gao J,
989 Sun Q-H, Hu H, Wang C-C (2006) Heat shock protein 70
990 inhibits alpha-synuclein fibril formation via interactions
991 with diverse intermediates. *J Mol Biol* **364**, 323-336.
- [76] Dedmon MM, Christodoulou J, Wilson MR, Dobson CM
992 (2005) Heat shock protein 70 inhibits α -synuclein fibril
993 formation via preferential binding to prefibrillar species.
994 *J Biol Chem* **280**, 14733-14740.
- [77] Redeker V, Pemberton S, Bienvenut W, Bousset L, Melki
995 R (2012) Identification of protein interfaces between α -
996 synuclein, the principal component of Lewy bodies in
997 Parkinson disease, and the molecular chaperones human
998 Hsc70 and the yeast Ssa1p. *J Biol Chem* **287**, 32630-
999 32639.
- [78] Roodveldt C, Bertocini CW, Andersson A, van der Goot
1000 AT, Hsu S-T, Fernández-Montesinos R, de Jong J, van
1001 Ham TJ, Nollen EA, Pozo D, Christodoulou J, Dobson CM
1002 (2009) Chaperone proteostasis in Parkinson's disease: Sta-
1003 bilization of the Hsp70/alpha-synuclein complex by Hip.
1004 *EMBO J* **28**, 3758-3770.
- [79] Aprile FA, Arosio P, Fusco G, Chen SW, Kumita JR,
1005 Dhulesia A, Tortora P, Knowles TPJ, Vendruscolo M, Dob-
1006 son CM, Cremades N (2017) Inhibition of α -synuclein
1007 fibril elongation by Hsp70 is governed by a kinetic binding
1008 competition between α -synuclein species. *Biochemistry*
1009 **56**, 1177-1180.
- [80] Pemberton S, Madiona K, Pieri L, Kabani M, Bousset L,
1010 Melki R (2011) Hsc70 protein interaction with soluble and
1011 fibrillar α -synuclein. *J Biol Chem* **286**, 34690-34699.
- [81] Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman
1012 BT (2006) Detection of novel intracellular α -synuclein
1013 oligomeric species by fluorescence lifetime imaging.
1014 *FASEB J* **20**, 2050-2057.
- [82] Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto
1015 T, Glabe C, Hyman BT, McLean PJ (2010) Heat-shock
1016 protein 70 modulates toxic extracellular α -synuclein
1017 oligomers and rescues trans-synaptic toxicity. *FASEB J*
1018 **25**, 326-336.
- [83] Auluck PK, Chan HYE, Trojanowski JQ, Lee VMY,
1019 Bonini NM (2002) Chaperone suppression of alpha-
1020 synuclein toxicity in a Drosophila model for Parkinson's
1021 disease. *Science* **295**, 865-868.
- [84] Hinault MP, Cuendet AFH, Mattoo RUH, Mensi M,
1022 Dietler G, Lashuel HA, Goloubinoff P (2010) Stable α -
1023 synuclein oligomers strongly inhibit chaperone activity of
1024 the Hsp70 system by weak interactions with J-domain
1025 co-chaperones. *J Biol Chem* **285**, 38173-38182.
- [85] Kampinga HH, Craig EA (2010) The HSP70 chaperone
1026 machinery: J proteins as drivers of functional specificity.
1027 *Nat Rev Mol Cell Biol* **11**, 579-592.

- [86] Craig EA, Marszalek J (2017) How do J-proteins get Hsp70 to do so many different things? *Trends Biochem Sci* **42**, 355-368.
- [87] Hageman J, Rujano MA, van Waarde MAWH, Kakkar V, Dirks RP, Govorukhina N, Oosterveld-Hut HMJ, Lubsen NH, Kampinga HH (2010) A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. *Mol Cell* **37**, 355-369.
- [88] Månsson C, Arosio P, Hussein R, Kampinga HH, Hashem RM, Boelens WC, Dobson CM, Knowles TPJ, Linse S, Emanuelsson C (2014) Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (A β 42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. *J Biol Chem* **289**, 31066-31076.
- [89] Mok S-A, Condello C, Freilich R, Gillies A, Arhar T, Oroz J, Kadavath H, Julien O, Assimon VA, Rauch JN, Duniak BM, Lee J, Tsai FTF, Wilson MR, Zweckstetter M, Dickey CA, Gestwicki JE (2018) Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. *Nat Struct Mol Biol* **25**, 384-393.
- [90] Gao X, Carroni M, Nussbaum-Krammer C, Mogk A, Nillegoda NB, Szlachcic A, Guilbride DL, Saibil HR, Mayer MP, Bukau B (2015) Human Hsp70 disaggregase reverses Parkinson's-linked α -synuclein amyloid fibrils. *Mol Cell* **59**, 781-793.
- [91] Duennwald ML, Echeverria A, Shorter J (2012) Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. *PLoS Biol* **10**, e1001346.
- [92] Dikic I (2017) Proteasomal and autophagic degradation systems. *Annu Rev Biochem* **86**, 193-224.
- [93] Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) α -synuclein is degraded by both autophagy and the proteasome. *J Biol Chem* **278**, 25009-25013.
- [94] Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. *Science* **305**, 1292-1295.
- [95] Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L (2008) Wild type α -synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. *J Biol Chem* **283**, 23542-23556.
- [96] Lee H-J, Khoshaghideh F, Patel S, Lee SJ (2004) Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. *J Neurosci* **24**, 1888-1896.
- [97] Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, Clark LN, Duff KE (2009) Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric α -synuclein. *Am J Pathol* **175**, 736-747.
- [98] Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999) Degradation of alpha-synuclein by proteasome. *J Biol Chem* **274**, 33855-33858.
- [99] Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, McLean PJ, Unni VK (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α -synuclein. *J Neurosci* **31**, 14508-14520.
- [100] Emmanouilidou E, Stefanis L, Vekrellis K (2010) Cell-produced α -synuclein oligomers are targeted to, and impair, the 26S proteasome. *Neurobiol Aging* **31**, 953-968.
- [101] Yan JQ, Yuan YH, Gao YN, Huang JY, Ma KL, Gao Y, Zhang WQ, Guo XF, Chen NH (2014) Overexpression of human E46K mutant α -Synuclein impairs macroautophagy via inactivation of JNK1-Bcl-2 pathway. *Mol Neurobiol* **50**, 685-701.
- [102] Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, Lichtenberg M, Menzies FM, Ravikumar B, Imarisio S, Brown S, O'Kane CJ, Rubinsztein DC (2010) α -Synuclein impairs macroautophagy: Implications for Parkinson's disease. *J Cell Biol* **190**, 1023-1037.
- [103] Song JX, Lu JH, Liu LF, Chen LL, Durairajan SSK, Yue Z, Zhang HQ, Li M (2014) HMGB1 is involved in autophagy inhibition caused by SNCA/ α -synuclein overexpression: A process modulated by the natural autophagy inducer corynoxine B. *Autophagy* **10**, 144-154.
- [104] Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. *J Neurosci* **21**, 9549-9560.
- [105] Tatebe H, Watanabe Y, Kasai T, Mizuno T, Nakagawa M, Tanaka M, Tokuda T (2010) Extracellular neurosin degrades α -synuclein in cultured cells. *Neurosci Res* **67**, 341-346.
- [106] Sung JY, Park SM, Lee C-H, Um JW, Lee HJ, Kim J, Oh YJ, Lee S-T, Paik SR, Chung KC (2005) Proteolytic cleavage of extracellular secreted α -synuclein via matrix metalloproteinases. *J Biol Chem* **280**, 25216-25224.
- [107] Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ (2005) The Co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates α -synuclein degradation decisions between proteasomal and lysosomal pathways. *J Biol Chem* **280**, 23727-23734.
- [108] Rott R, Szargel R, Haskin J, Bandopadhyay R, Lees AJ, Shani V, Engelender S (2011) α -Synuclein fate is determined by USP9X-regulated monoubiquitination. *Proc Natl Acad Sci U S A* **108**, 18666-18671.
- [109] Tofaris GK, Kim HT, Hourez R, Jung J-W, Kim KP, Goldberg AL (2011) Ubiquitin ligase Nedd4 promotes α -synuclein degradation by the endosomal-lysosomal pathway. *Proc Natl Acad Sci U S A* **108**, 17004-17009.
- [110] Levine PM, Galesic A, Balana AT, Mahul-Mellier A-L, Navarro MX, De Leon CA, Lashuel HA, Pratt MR (2019) α -Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease. *Proc Natl Acad Sci U S A* **116**, 1511-1519.
- [111] Martınez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu D, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. *J Clin Invest* **118**, 777-788.
- [112] Tenreiro S, Reimão-Pinto MM, Antas P, Rino J, Wawrzyszka D, Macedo D, Rosado-Ramos R, Amen T, Waiss M, Magalhães F, Gomes A, Santos CN, Kaganovich D, Outeiro TF (2014) Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. *PLoS Genet* **10**, e1004302.
- [113] Oueslati A, Schneider BL, Aebischer P, Lashuel HA (2013) Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. *Proc Natl Acad Sci U S A* **110**, E3945-E3954.
- [114] Dahmene M, Bérard M, Oueslati A (2017) Dissecting the molecular pathway involved in PLK2 kinase-mediated α -

- synuclein-selective autophagic degradation. *J Biol Chem* **292**, 3919-3928.
- [115] Collins GA, Goldberg AL (2017) The logic of the 26S proteasome. *Cell* **169**, 792-806.
- [116] Liu CW, Corboy MJ, DeMartino GN, Thomas PJ (2003) Endoproteolytic activity of the proteasome. *Science* **299**, 408-411.
- [117] Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. *Science* **293**, 263-269.
- [118] Tofaris GK, Layfield R, Spillantini MG (2001) α -Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. *FEBS Lett* **509**, 22-26.
- [119] Machiya Y, Hara S, Arawaka S, Fukushima S, Sato H, Sakamoto M, Koyama S, Kato T (2010) Phosphorylated α -Synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. *J Biol Chem* **285**, 40732-40744.
- [120] Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani E, Avraham E, Engelender S (2008) Monoubiquitylation of α -Synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. *J Biol Chem* **283**, 3316-3328.
- [121] Lee JT, Wheeler TC, Li L, Chin LS (2008) Ubiquitination of α -synuclein by Siah-1 promotes α -synuclein aggregation and apoptotic cell death. *Hum Mol Genet* **17**, 906-917.
- [122] Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. *Neuron* **36**, 1007-1019.
- [123] Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, Dawson V, Dawson TM, Ross CA (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. *Hum Mol Genet* **10**, 919-926.
- [124] Vidyadhara DJ, Lee JE, Chandra SS (2019) Role of the endolysosomal system in Parkinson's disease. *J Neurochem* **150**, 487-506.
- [125] Xilouri M, Brekk OR, Stefanis L (2016) Autophagy and alpha-synuclein: Relevance to Parkinson's disease and related synucleopathies. *Mov Disord* **31**, 178-192.
- [126] Kaur J, Debnath J (2015) Autophagy at the crossroads of catabolism and anabolism. *Nat Rev Mol Cell Biol* **16**, 461-472.
- [127] Lilienbaum A (2013) Relationship between the proteasomal system and autophagy. *Int J Biochem Mol Biol* **4**, 1-26.
- [128] Sontag EM, Samant RS, Frydman J (2017) Mechanisms and functions of spatial protein quality control. *Annu Rev Biochem* **86**, 97-122.
- [129] Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* **441**, 885-889.
- [130] Kim M, Sandford E, Gatica D, Qiu Y, Liu X, Zheng Y, Schulman BA, Xu J, Semple I, Ro SH, Kim B, Mavioglu RN, Tolun A, Jipa A, Takats S, Karpati M, Li JZ, Yapici Z, Juhasz G, Lee JH, Klionsky DJ, Burmeister M (2016) Mutation in ATG5 reduces autophagy and leads to ataxia with developmental delay. *Elife* **5**, 1-18.
- [131] Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. *J Neurosci* **29**, 13578-13588.
- [132] Levine B, Liu R, Dong X, Zhong Q (2015) Beclin orthologs: Integrative hubs of cell signaling, membrane trafficking, and physiology. *Trends Cell Biol* **25**, 533-544.
- [133] Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E, Schlötzer-Schrehardt U, Hyman BT, McLean PJ, Masliah E, Winkler J (2012) Alpha-synuclein aggregation involves a bafilomycin A1-sensitive autophagy pathway. *Autophagy* **8**, 754-766.
- [134] Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR, Lee VMY (2013) Lewy body-like α -synuclein aggregates resist degradation and impair macroautophagy. *J Biol Chem* **288**, 15194-15210.
- [135] Choubey V, Safulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A (2011) Mutant A53T α -Synuclein induces neuronal death by increasing mitochondrial autophagy. *J Biol Chem* **286**, 10814-10824.
- [136] Chen L, Xie Z, Turkson S, Zhuang X (2015) A53T Human α -synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. *J Neurosci* **35**, 890-905.
- [137] Gao J, Perera G, Bhadbhade M, Halliday GM, Dzamko N (2019) Autophagy activation promotes clearance of α -synuclein inclusions in fibril-seeded human neural cells. *J Biol Chem* **294**, 14241-14256.
- [138] Chiang HL, Terlecky SR, Plant CP, Dice JF (1989) A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. *Science* **246**, 382-385.
- [139] Cuervo AM, Dice JF (1996) A receptor for the selective uptake and degradation of proteins by lysosomes. *Science* **273**, 501-503.
- [140] Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, Schapira AHV (2010) Chaperone-mediated autophagy markers in Parkinson disease brains. *Arch Neurol* **67**, 1464-1472.
- [141] Alvarez-Erviti L, Seow Y, Schapira AHV, Rodriguez-Oroz MC, Obeso JA, Cooper JM (2013) Influence of microRNA deregulation on chaperone-mediated autophagy and α -synuclein pathology in parkinson's disease. *Cell Death Dis* **4**, e545-e548.
- [142] Li G, Yang H, Zhu D, Huang H, Liu G, Lun P (2014) Targeted suppression of chaperone-mediated autophagy by miR-320a promotes α -synuclein aggregation. *Int J Mol Sci* **15**, 15845-15857.
- [143] Murphy KE, Gysbers AM, Abbott SK, Spiro AS, Furuta A, Cooper A, Garner B, Kabuta T, Halliday GM (2015) Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. *Mov Disord* **30**, 1639-1647.
- [144] Rothaug M, Stroobants S, Schweizer M, Peters J, Zunke F, Allerding M, D'Hooge R, Saftig P, Blanz J (2015) LAMP-2 deficiency leads to hippocampal dysfunction but normal clearance of neuronal substrates of chaperone-mediated autophagy in a mouse model for Danon disease. *Acta Neuropathol Commun* **3**, 6.

- 1302 [145] Xilouri M, Brekk OR, Polissidis A, Chrysanthou-
1303 Piterou M, Kloukina I, Stefanis L (2016) Impairment
1304 of chaperone-mediated autophagy induces dopaminergic
1305 neurodegeneration in rats. *Autophagy* **12**, 2230-2247. 1352
- 1306 [146] Sevlever D, Jiang P, Yen S-HCHC (2008) Cathepsin D is
1307 the main lysosomal enzyme involved in the degradation
1308 of α -synuclein and generation of its carboxy-terminally
1309 truncated species. *Biochemistry* **47**, 9678-9687. 1353
- 1310 [147] Qiao L, Hamamichi S, Caldwell KA, Caldwell GA,
1311 Yacoubian TA, Wilson S, Xie ZL, Speake LD, Parks R,
1312 Crabtree D, Liang Q, Crimmins S, Schneider L, Uchiyama
1313 Y, Iwatsubo T, Zhou Y, Peng L, Lu YM, Standaert DG,
1314 Walls KC, Shacka JJ, Roth KA, Zhang J (2008) Lysoso-
1315 mal enzyme cathepsin D protects against alpha-synuclein
1316 aggregation and toxicity. *Mol Brain* **1**, 17. 1354
- 1317 [148] Cullen V, Lindfors M, Ng J, Paetau A, Swinton E,
1318 Kolodziej P, Boston H, Saftig P, Wouffe J, Feany MB,
1319 Myllykangas L, Schlossmacher MG, Tyynelä J (2009)
1320 Cathepsin D expression level affects alpha-synuclein pro-
1321 cessing, aggregation, and toxicity in vivo. *Mol Brain* **2**,
1322 1-17. 1355
- 1323 [149] Pastores GM, Hughes DA (2000) Gaucher disease. In
1324 *GeneReviews® [Internet]*, Adam MP, Ardinger HH,
1325 Pagon RA, Wallace SE, eds. University of Washington,
1326 Seattle, WA. 1356
- 1327 [150] Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J,
1328 Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice
1329 A, Chen C-M, Clark LN, Condroyer C, De Marco E V,
1330 Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung H-C, Gan-
1331 Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A,
1332 Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen G-
1333 J, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J,
1334 Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger
1335 A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosen-
1336 baum H, Rozenberg R, Samii A, Samadpour T, Schulte C,
1337 Sharma M, Singleton A, Spitz M, Tan E-K, Tayebi N, Toda
1338 T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu
1339 Y-R, Zabetian CP, Zhao Y, Ziegler SG (2009) Multicenter
1340 analysis of glucocerebrosidase mutations in Parkinson's
1341 disease. *N Engl J Med* **361**, 1651-1661. 1357
- 1342 [151] Manning-Boğ AB, Schüle B, Langston JW (2009)
1343 Alpha-synuclein-glucocerebrosidase interactions in phar-
1344 macological Gaucher models: A biological link between
1345 Gaucher disease and parkinsonism. *Neurotoxicology* **30**,
1346 1127-1132. 1358
- 1347 [152] Cleeter MWJ, Chau KY, Gluck C, Mehta A, Hughes
1348 DA, Duchon M, Wood NW, Hardy J, Mark Cooper J,
1349 Schapira AH (2013) Glucocerebrosidase inhibition causes
1350 mitochondrial dysfunction and free radical damage. *Neu-
1351 rochem Int* **62**, 1-7. 1359
- [153] Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA
(2011) Accumulation and distribution of β -synuclein and
ubiquitin in the CNS of Gaucher disease mouse models.
Mol Genet Metab **102**, 436-447. 1360
- [154] Fishbein I, Kuo YM, Giasson BI, Nussbaum RL (2014)
Augmentation of phenotype in a transgenic Parkinson
mouse heterozygous for a Gaucher mutation. *Brain* **137**,
3235-3247. 1361
- [155] Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Tre-
leaven CM, Bu J, Sweet L, Passini MA, Dodge JC, Yu
WH, Sidman RL, Cheng SH, Shihabuddin LS (2013) Aug-
menting CNS glucocerebrosidase activity as a therapeutic
strategy for parkinsonism and other Gaucher-related synu-
cleinopathies. *Proc Natl Acad Sci U S A* **110**, 3537-3542. 1362
- [156] Woodard CM, Campos BA, Kuo SH, Nirenberg MJ,
Nestor MW, Zimmer M, Mosharov EV, Sulzer D, Zhou
H, Paull D, Clark L, Schadt EE, Sardi SP, Rubin L, Eggan
K, Brock M, Lipnick S, Rao M, Chang S, Li A, Noggle SA
(2014) iPSC-derived dopamine neurons reveal differences
between monozygotic twins discordant for parkinson's
disease. *Cell Rep* **9**, 1173-1182. 1363
- [157] Schöndorf DC, Aureli M, McAllister FE, Hindley CJ,
Mayer F, Schmid B, Sardi SP, Valsecchi M, Hoffmann
S, Schwarz LK, Hedrich U, Berg D, Shihabuddin LS,
Hu J, Pruszk J, Gygi SP, Sonnino S, Gasser T, Deleidi
M (2014) iPSC-derived neurons from GBA1-associated
Parkinson's disease patients show autophagic defects and
impaired calcium homeostasis. *Nat Commun* **5**, 4028. 1364
- [158] Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Cald-
well GA, Sidransky E, Grabowski GA, Krainc D (2011)
Gaucher disease glucocerebrosidase and α -synuclein form
a bidirectional pathogenic loop in synucleinopathies. *Cell*
146, 37-52. 1365
- [159] Gegg ME, Burke D, Heales SJR, Cooper JM, Hardy J,
Wood NW, Schapira AHV (2012) Glucocerebrosidase
deficiency in substantia nigra of parkinson disease brains.
Ann Neurol **72**, 455-463. 1366
- [160] Bae EJ, Yang NY, Song M, Lee CS, Lee JS, Jung BC, Lee
HJ, Kim S, Masliah E, Sardi SP, Lee SJ (2014) Glucocere-
brosidase depletion enhances cell-to-cell transmission of
 α -synuclein. *Nat Commun* **5**, 1-11. 1367
- [161] Bae EJ, Yang NY, Lee C, Lee HJ, Kim S, Sardi SP, Lee
SJ (2015) Loss of glucocerebrosidase 1 activity causes
lysosomal dysfunction and α -synuclein aggregation. *Exp
Mol Med* **47**, e153-e158. 1368
- [162] Wentink A, Nussbaum-Krammer C, Bukau B (2019) Mod-
ulation of amyloid states by molecular chaperones. *Cold
Spring Harb Perspect Biol* **11**, a033969. 1369